文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

临床分离株中黏菌素耐药性的流行情况：一项系统评价和荟萃分析。

Prevalence of colistin resistance in clinical isolates of : a systematic review and meta-analysis.

作者信息

Narimisa Negar, Keshtkar Abbasali, Dadgar-Zankbar Leila, Bostanghadiri Narjess, Far Yasaman Rouein, Shahroodian Soheila, Zahedi Bialvaei Abed, Razavi Shabnam

机构信息

Microbial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.

Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

出版信息

Front Microbiol. 2024 Oct 9;15:1477836. doi: 10.3389/fmicb.2024.1477836. eCollection 2024.

DOI:10.3389/fmicb.2024.1477836
PMID:39473844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11520190/
Abstract

OBJECTIVE: The emergence of resistance to colistin, the last resort for treating severe infections caused by , poses a significant threat to public health. This meta-analysis aimed to investigate the prevalence of colistin resistance in clinical isolates of METHOD: A comprehensive search of MEDLINE (PubMed), Web of Science, and Scopus databases was conducted to identify relevant articles published until December 2023. Subsequently, a meta-analysis was performed using Stata software to examine the pooled prevalence of colistin resistance and to conduct subgroup analyses. RESULTS: A total of 619 studies were included in the meta-analysis, revealing a global prevalence of colistin resistance of 1% among all isolates. Furthermore, cystic fibrosis patients exhibited the highest resistance to colistin, with a prevalence of 7% among the examined diseases. CONCLUSION: The increase in colistin resistance in in recent years from 2% (in the period of 2006-2010) to 5% (in the period of 2020-2023) underscores the need for implementing infection prevention programs, using appropriate treatment regimens, and disseminating comprehensive information on antimicrobial resistance patterns. These measures are crucial for addressing this growing public health concern.

摘要

目的：对粘菌素产生耐药性，这是治疗由[未提及病原体]引起的严重感染的最后手段，对公众健康构成重大威胁。本荟萃分析旨在调查[未提及病原体]临床分离株中粘菌素耐药性的流行情况。 方法：对MEDLINE（PubMed）、科学网和Scopus数据库进行全面检索，以确定截至2023年12月发表的相关文章。随后，使用Stata软件进行荟萃分析，以检查粘菌素耐药性的合并流行率并进行亚组分析。 结果：共有619项研究纳入荟萃分析，结果显示在所有[未提及病原体]分离株中，粘菌素耐药性的全球流行率为1%。此外，囊性纤维化患者对粘菌素的耐药性最高，在所检查的疾病中流行率为7%。 结论：近年来，[未提及病原体]中粘菌素耐药性从2%（2006 - 2010年期间）增加到5%（2020 - 2023年期间），这凸显了实施感染预防计划、采用适当治疗方案以及传播有关抗菌药物耐药模式的全面信息的必要性。这些措施对于解决这一日益严重的公共卫生问题至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/4699cd03f9dd/fmicb-15-1477836-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/f4692e24b059/fmicb-15-1477836-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/781640025ca8/fmicb-15-1477836-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/9c3db95f9813/fmicb-15-1477836-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/91da587c87cc/fmicb-15-1477836-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/0f1a9f2fc7e7/fmicb-15-1477836-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/edcb26e62be5/fmicb-15-1477836-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/2b27c1a83763/fmicb-15-1477836-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/6cdc3db0abed/fmicb-15-1477836-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/56085ef327b0/fmicb-15-1477836-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/0d7fad6c2d48/fmicb-15-1477836-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/4699cd03f9dd/fmicb-15-1477836-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/f4692e24b059/fmicb-15-1477836-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/781640025ca8/fmicb-15-1477836-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/9c3db95f9813/fmicb-15-1477836-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/91da587c87cc/fmicb-15-1477836-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/0f1a9f2fc7e7/fmicb-15-1477836-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/edcb26e62be5/fmicb-15-1477836-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/2b27c1a83763/fmicb-15-1477836-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/6cdc3db0abed/fmicb-15-1477836-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/56085ef327b0/fmicb-15-1477836-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/0d7fad6c2d48/fmicb-15-1477836-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d5/11520190/4699cd03f9dd/fmicb-15-1477836-g011.jpg

相似文献

[1]
Prevalence of colistin resistance in clinical isolates of : a systematic review and meta-analysis.

Front Microbiol. 2024-10-9

[2]
Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: A systematic review and meta-analysis.

Microb Pathog. 2022-4

[3]
Antimicrobial resistance profile of Pseudomonas aeruginosa clinical isolates from healthcare-associated infections in Ethiopia: A systematic review and meta-analysis.

PLoS One. 2024

[4]
Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis.

Antimicrob Resist Infect Control. 2024-2-28

[5]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[6]
Prevalence of colistin resistance of Klebsiella pneumoniae isolates in Iran: a systematic review and meta-analysis.

Ann Clin Microbiol Antimicrob. 2022-6-28

[7]
Global prevalence of mutation in the gene among clinical isolates of colistin-resistant : a systematic review and meta-analysis.

Front Microbiol. 2024-6-7

[8]
Prevalence of meropenem-resistant Pseudomonas Aeruginosa in Ethiopia: a systematic review and meta‑analysis.

Antimicrob Resist Infect Control. 2024-4-10

[9]
Worldwide Prevalence of -mediated Colistin-Resistance in Isolates of Clinical Samples, Healthy Humans, and Livestock-A Systematic Review and Meta-Analysis.

Pathogens. 2022-6-8

[10]
Global Prevalence of Colistin Resistance in from Bloodstream Infection: A Systematic Review and Meta-Analysis.

Pathogens. 2022-9-24

引用本文的文献

[1]
Colistin resistance in the era of antimicrobial resistance: challenges and strategic countermeasures.

Folia Microbiol (Praha). 2025-9-1

[2]
In Vitro Antimicrobial Activity of the Novel Antimicrobial Peptide OMN51 Against Multi-Drug-Resistant Isolated from People with Cystic Fibrosis.

J Clin Med. 2025-7-23

[3]
The genomic configurations driving antimicrobial resistance and virulence in colistin resistant Pseudomonas aeruginosa from an Egyptian Tertiary Oncology Hospital.

PLOS Glob Public Health. 2025-8-5

[4]
Global prevalence and antibiotic resistance profiles of carbapenem-resistant reported from 2014 to 2024: a systematic review and meta-analysis.

Front Microbiol. 2025-7-21

[5]
The Genetic Background and Culture Medium Only Marginally Affect the In Vitro Evolution of Toward Colistin Resistance.

Antibiotics (Basel). 2025-6-13

[6]
Efficacy of Endolysin LysAB1245 Combined with Colistin as Adjunctive Therapy Against Colistin-Resistant Gram-Negative Bacteria.

Antibiotics (Basel). 2025-5-23

[7]
Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.

Sci Rep. 2025-5-8

[8]
Colistin Treatment Outcomes in Gram-Negative Bacterial Infections in the Northeast of Romania: A Decade of Change Through Pandemic Challenges.

Antibiotics (Basel). 2025-3-7

[9]
A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.

Antibiotics (Basel). 2025-2-21

[10]
Trends of Colistin MIC Among and at a First-Class Hospital in Vietnam.

J Trop Med. 2025-3-16

本文引用的文献

[1]
Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis.

Antimicrob Resist Infect Control. 2024-2-28

[2]
Evaluation of different methods for susceptibility testing of colistin in carbapenem resistant Gram-negative bacilli.

Access Microbiol. 2023-10-16

[3]
Distribution and Drug Resistance of Bacterial Infection in Hospitalized Patients at the Respiratory Department before and after the COVID-19 Pandemic in Guangzhou, China.

Microorganisms. 2023-10-12

[4]
Comparative evaluation of colistin broth disc elution (CBDE) and broth microdilution (BMD) in clinical isolates of Pseudomonas aeruginosa with special reference to heteroresistance.

Indian J Med Microbiol. 2024

[5]
Antibacterial and Anti-Efflux Activities of Cinnamon Essential Oil against Pan and Extensive Drug-Resistant Isolated from Human and Animal Sources.

Antibiotics (Basel). 2023-10-5

[6]
Prevalence and antibiogram of bacteria causing urinary tract infection among patients with chronic kidney disease.

Open Med (Wars). 2023-10-19

[7]
Phage-antibiotic combinations against multidrug-resistant in static and dynamic biofilm models.

Antimicrob Agents Chemother. 2023-11-15

[8]
Distribution of multidrug-resistant bacterial infections in diabetic foot ulcers and risk factors for drug resistance: a retrospective analysis.

PeerJ. 2023

[9]
Multidrug-resistant Gram-negative bacterial infections and associated factors in a Kenyan intensive care unit: a cross-sectional study.

Ann Clin Microbiol Antimicrob. 2023-9-14

[10]
In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017-2021.

J Glob Antimicrob Resist. 2023-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索